Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri
This program has been made available online.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Board-certified psychiatric pharmacist provides information on the pharmacokinetics and administration of long-acting injectable antipsychotics, from Clinical Care Options (CCO)
In this on-demand webcast, an expert faculty explores updates on identifying and managing tardive dyskinesia.
In this on-demand webcast, an expert faculty describes the current and emerging treatment options for major depression
Expert presentation on current and emerging treatments for bipolar depression with a focus on treatment with monoaminergic antidepressants, mood stabilizers, and specific second-generation antipsychotics, from Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.